‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

BACKGROUND: The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension. METHODS: Atta...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Neurol
Autori principali: Vissing, John, Jacob, Saiju, Fujita, Kenji P., O’Brien, Fanny, Howard, James F.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2020
Soggetti:
Original Communication
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7320935/
https://ncbi.nlm.nih.gov/pubmed/32189108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-020-09770-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi